Robert L. Nussbaum is Chief Medical Officer at Invitae Corp (NVTA). They have made 22 open-market trades across 1 company since 2017, most recently 2023-12-20.
CIK 0001640322
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 22 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVTA | 551,941 | $49K |
Shares reported on the most recent Form 4, priced at the 2023-12-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVTA | SELL | 2023-06-13 | 2023-06-15 | $1.38 | $10K | -9.9% | -2.0% | -36.2% |
| NVTA | SELL | 2023-05-16 | 2023-05-18 | $1.20 | $32K | -7.0% | +5.2% | -11.3% |
| NVTA | SELL | 2023-03-13 | 2023-03-15 | $1.41 | $4K | -10.0% | -2.1% | +1.4% |
| NVTA | SELL | 2022-08-16 | 2022-08-18 | $4.55 | $32K | -19.1% | -14.5% | -14.2% |
| NVTA | SELL | 2022-05-17 | 2022-05-19 | $3.81 | $23K | -12.0% | -40.8% | +11.3% |
| NVTA | SELL | 2022-03-14 | 2022-03-16 | $6.69 | $262K | +9.8% | -17.1% | -70.0% |
| NVTA | SELL | 2021-11-11 | 2021-11-15 | $21.89 | $1.3M | -15.9% | -22.8% | -50.9% |
| NVTA | SELL | 2021-08-16 | 2021-08-18 | $25.42 | $1.1M | +16.4% | +26.2% | -12.4% |
| NVTA | SELL | 2021-06-14 | 2021-06-16 | $31.63 | $627K | +15.6% | -4.5% | -0.1% |
| NVTA | SELL | 2021-03-15 | 2021-03-19 | $42.90 | $1.6M | -7.7% | -14.7% | -22.0% |
| NVTA | SELL | 2021-03-12 | 2021-03-17 | $42.90 | $1.6M | -20.3% | -9.3% | -26.5% |
| NVTA | SELL | 2020-09-10 | 2020-09-14 | $33.56 | $1.5M | +20.3% | +38.8% | +52.7% |
| NVTA | SELL | 2020-08-19 | 2020-08-20 | $32.10 | $1.2M | +8.8% | +20.4% | +35.4% |
| NVTA | SELL | 2020-07-09 | 2020-07-13 | $34.15 | $2.0M | -4.6% | -8.4% | +57.4% |
| NVTA | SELL | 2020-05-20 | 2020-05-22 | $17.13 | $917K | -7.1% | +50.8% | +88.1% |
| NVTA | SELL | 2020-03-16 | 2020-03-16 | $11.79 | $252K | +62.1% | +34.5% | +69.2% |
| NVTA | SELL | 2019-08-19 | 2019-08-21 | $25.29 | $1.0M | -14.3% | -18.2% | -26.7% |
| NVTA | SELL | 2019-05-20 | 2019-05-22 | $18.21 | $262K | +3.1% | +20.1% | +43.6% |
| NVTA | SELL | 2019-01-10 | 2019-01-14 | $14.01 | $146K | +8.4% | +14.7% | +83.5% |
| NVTA | SELL | 2018-11-12 | 2019-01-14 | $13.11 | $137K | +8.4% | +14.7% | +83.5% |
| NVTA | SELL | 2018-05-15 | 2018-05-16 | $6.96 | $47K | +12.0% | +23.8% | +53.4% |
| NVTA | SELL | 2017-02-15 | 2017-02-15 | $9.53 | $16K | +2.1% | +2.6% | -4.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.